The insured patients who suffer from high blood pressure will benefit from the compensated medicine with the international denomination, nebivololum from April 1.
According to the Health Ministry, the decision on extending the therapeutic indications for the nebivololum preparation belongs to the council for medicines compensated from the Mandatory Health Insurances Accounts (FAOAM).
Thus, the medicine used for the treatment of cardiovascular diseases will be prescribed not only to patients with heart insufficiency, but also to those with high blood pressure, no matter the age.
The preparation will be compensated at the level of 80 per cent of the average retail price of two commercial denominations present on market. About 70,000 people are to annually benefit from nebivololum and the annual average cost reimbursed per patient is 675 lei. (Moldpres/Business World Magazine)